NEW YORK (GenomeWeb) – Pressure BioSciences said on Thursday that it has engaged investment bank IssuWorks to review strategic and financing alternatives, including the potential spin off of "vertical market applications into new, stand-alone businesses."

In a statement, Pressure Bio CEO Richard Schumacher said that with the help of IssuWorks, "we will immediately begin to look at various … alternatives that we believe have the potential to result in the generation of increased value for all shareholders of" the company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.